Aug 18, 2026 04:15PM
Aug 13, 2026 07:00AM
Jul 17, 2026 04:15PM
Jun 17, 2026 04:15PM
Jun 11, 2026 04:15PM
Jun 2, 2026 07:05PM
Jun 2, 2026 07:05PM Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026 Congress and Publis
May 28, 2026 07:05AM
May 19, 2026 07:05AM
May 19, 2026 07:05AM
May 18, 2026 04:15PM
May 13, 2026 06:50AM
May 13, 2026 06:50AM
May 13, 2026 06:00AM Zenas BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Update
Apr 17, 2026 04:15PM
Mar 27, 2026 12:13AM
Mar 27, 2026 12:12AM
Mar 26, 2026 04:01PM
Mar 26, 2026 04:01PM
Mar 16, 2026 06:01PM
Mar 16, 2026 07:00AM Zenas BioPharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Feb 20, 2026 04:15PM
Feb 9, 2026 07:05AM
Feb 9, 2026 07:05AM
Feb 4, 2026 07:05AM
Jan 16, 2026 04:15PM
Jan 5, 2026 07:05AM
Jan 5, 2026 07:05AM Zenas BioPharma Announces Positive Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD)
Dec 19, 2025 04:15PM
Dec 15, 2025 07:05AM
Dec 15, 2025 07:05AM
Nov 12, 2025 07:05AM
Nov 11, 2025 07:05AM
Oct 27, 2025 07:05AM
Oct 27, 2025 07:05AM Zenas BioPharma Announces Positive Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis
Oct 8, 2025 05:00AM
Oct 8, 2025 05:00AM
Sep 2, 2025 07:15AM
Sep 2, 2025 07:15AM
Sep 2, 2025 07:05AM
Aug 26, 2025 07:05AM
Aug 12, 2025 07:05AM Zenas BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
Jun 20, 2025 04:15PM
May 29, 2025 07:05AM
May 15, 2025 07:05AM
Apr 17, 2025 04:20PM
Apr 7, 2025 07:06AM
Apr 7, 2025 07:05AM
Mar 17, 2025 07:05AM Zenas BioPharma (ZBIO) Appoints Lisa von Moltke as Chief Medical Officer
Mar 17, 2025 07:05AM

1,185,380 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All